Health-care companies were more or less flat as traders rotated out of the high-risk tech sector into defensive areas.
Eli Lilly launched its Foundayo weight-loss pill in the U.K., making the country the first in Europe to offer the oral treatment.
Moderna slipped but remained sharply higher for the year to date as investors remained optimistic about a breakthrough of RNA technology in oncology.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.